Cooperation Advantage
Creative system: Government guidance, enterprise-like operation, integration of resources and speed-up development
South China Center for Innovative Pharmaceuticals (“SCCIP”) is a private non-enterprise organization in science sector devoted to new drug innovation and general services with its major feature being system innovation.
Guangdong South China New Drug Innovation Co., Ltd. led by Guangdong Provincial Government with joint investment of key medical enterprises in Guangdong Province, university and research organization, announced its foundation in October, 2008. SCCIP is then founded with backing up of the company with finance supported to bring up a fully new model of system that is enterprise and research organization are jointly involved under the guidance of government. The governmental funds are used to carry out R&D and construction of platform for new drug innovation projects, participating himself to promote the medical enterprise and innovation company to affect the enterprise-like operation in SCCIP. Under the guidance of governmental funds and directive operation the SCCIP will integrate the high-quality resources in the region, set up a large scale platform for new drug innovation in South China, and technically support the new drug R&D. At the same time SCCIP will facilitate the new drug R&D and promote translation and industrialization of new drug projects through fund support and technical services, etc..
Strong economic strength
The first total investment of 700M Yuan has been allocated.
Specialized service covering overall pharmaceutical industrial chain
SCCIP will integrate internal and external technical resources to provide overall services covering information service, intellectual property, quality study and validation, animal experiment, clinical trial, new drug registration and so forth. The services cover various sectors on new drug innovation industry to assist project teams to enable their R&D capability in connection with new drug innovation chain and to improve their R&D efficiency and speed up progress of R&D and industrialization of projects.
Properly arranged specialized technical platform
Based on the need for improving both business competitiveness and independent innovation, the SCCIP will set up two types of platform systems by coordinately integrating regional innovation resources, of which one is the fundamental platform for the common need by biomedical industry, including quality study and validation, pilot, clinical trial, animal experiment, knowledge management, information service, intellectual property ,etc; the other is the specialized common platform which focuses on major field in pharmaceutical sector, such as vaccine platform, recombinant drugs platform, advanced formulation platform and translational medicine platform ,etc. With a total floor space of 36,800 square meters, including more than 25000 square meters for the labs, SCCIP is equipped with NMR, QTRAP and large scale biological reactor, etc. leading its hardware condition worldwide.
Specialized management team
Leading scientists in teams have their career in well-known scientific and research organizations and medical enterprises both at home and abroad, possessing full range of R&D capability, and enriched experience in terms of new drug management, new drug innovation planning and translation of scientific and research outcomes.
